Skip to content
You are now leaving https://www.ionispharma.com to visit

New Data Presented at Peripheral Nerve Society Meeting Further Support Potential Benefit of Inotersen

Significant benefit observed for both clinical measurements of neurological disease progression and quality of life at 8 and 15 months in patients with FAP CARLSBAD, Calif. , July 10, 2017 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) presented new top-line data from the Phase 3